Abstract | OBJECTIVE: PATIENTS AND METHODS: Between September 1991 and December 2000, 60 consecutive patients (24 women and 36 men) with haemorrhagic cystitis were primarily treated with SPP; 53 patients had had radical radiotherapy for pelvic malignancy and seven systemic cyclophosphamide. All patients were screened for blood dyscrasia and residual/primary urothelial malignancy with imaging, urine cytology and cystoscopy. RESULTS: In all, 51 patients were available for follow-up; the median (range) interval between completing treatment and developing haematuria was 4.5 (0.08-39.4) years, the duration of treatment 180 (21-1745) days and patients were followed for 450 (19-4526) days from the onset of haematuria. All patients were started on SPP at an initial dose of 100 mg three times daily. In 21 patients the dose was gradually reduced to a maintenance dose of 100 mg and in 10 further patients SPP was stopped because the haematuria stopped completely. Twenty patients died while on treatment from causes not directly related to their haematuria. CONCLUSION:
|
Authors | Sarbjinder S Sandhu, Miles Goldstraw, Christopher R J Woodhouse |
Journal | BJU international
(BJU Int)
Vol. 94
Issue 6
Pg. 845-7
(Oct 2004)
ISSN: 1464-4096 [Print] England |
PMID | 15476520
(Publication Type: Journal Article)
|
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- Pentosan Sulfuric Polyester
|
Topics |
- Anti-Inflammatory Agents, Non-Steroidal
(therapeutic use)
- Cystitis
(drug therapy, etiology)
- Female
- Hematuria
(drug therapy, etiology)
- Hemorrhage
(etiology, prevention & control)
- Humans
- Male
- Pelvic Neoplasms
(radiotherapy)
- Pentosan Sulfuric Polyester
(therapeutic use)
- Radiation Injuries
(drug therapy)
- Radiotherapy
(adverse effects)
- Retrospective Studies
- Urinary Bladder
(radiation effects)
|